RenovoRx (RNXT) Retained Earnings (2020 - 2026)
RenovoRx (RNXT) posted Retained Earnings of -$64.9 million for Q1 2026, down 5.72% sequentially from -$61.4 million in Q4 2025, and down 23.29% YoY from -$84.6 million in Q1 2025.
RenovoRx (RNXT) Retained Earnings (2020 - 2026) Analysis & Trends
RenovoRx has reported Retained Earnings for 7 years, with the latest figure at -$64.9 million in Q1 2026.
- Quarterly Retained Earnings fell 23.29% year-over-year to -$64.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$64.9 million (down 23.29% YoY) and the FY2025 annual result came in at -$61.4 million, down 22.24% from the prior year.
- Retained Earnings slipped to -$64.9 million in Q1 2026 per RNXT's latest filing, from -$61.4 million in the prior quarter.
- Over five years, Retained Earnings peaked at $54.1 million in Q2 2024 and troughed at -$64.9 million in Q1 2026.
- A 5-year average of -$37.7 million and a median of -$41.4 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings soared 247.12% in 2024, then sank 202.51% in 2025.
- Over 5 years, Retained Earnings stood at -$31.2 million in 2022, then sank by 32.82% to -$41.4 million in 2023, then decreased by 21.29% to -$50.2 million in 2024, then decreased by 22.24% to -$61.4 million in 2025, then retreated by 5.72% to -$64.9 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$64.9 million, -$61.4 million, and -$58.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | RenovoRx | 62.20 Mn | 62.20 Mn | 766,000.00 | -67.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -67.82 Mn |
| Mar 31, 2026 | -64.90 Mn |
| Dec 31, 2025 | -61.39 Mn |
| Sep 30, 2025 | -58.45 Mn |
| Jun 30, 2025 | -55.50 Mn |
| Mar 31, 2025 | -52.64 Mn |
| Dec 31, 2024 | -50.22 Mn |
| Sep 30, 2024 | -47.30 Mn |
| Jun 30, 2024 | 54.14 Mn |
| Mar 31, 2024 | -42.48 Mn |
| Dec 31, 2023 | -41.41 Mn |
| Sep 30, 2023 | -38.18 Mn |
| Jun 30, 2023 | -36.80 Mn |
| Mar 31, 2023 | -34.40 Mn |
| Dec 31, 2022 | -31.17 Mn |
| Sep 30, 2022 | -29.00 Mn |
| Jun 30, 2022 | -26.88 Mn |
| Mar 31, 2022 | -24.29 Mn |
| Dec 31, 2021 | -21.28 Mn |
| Sep 30, 2021 | 36.48 Mn |